Sign Up to like & get
recommendations!
1
Published in 2020 at "Oncoimmunology"
DOI: 10.1080/2162402x.2020.1846901
Abstract: ABSTRACT Metastatic clear cell renal cell carcinoma (mccRCC) benefits from several treatment options in the first-line setting with VEGFR inhibitors and/or immunotherapy including anti-PD-L1 or anti-PD1 agents. Identification of predictive biomarkers is highly needed to…
read more here.
Keywords:
levels spd;
clear cell;
spd spd;
cell renal ... See more keywords
Sign Up to like & get
recommendations!
2
Published in 2021 at "European Journal of Haematology"
DOI: 10.1111/ejh.13621
Abstract: The programmed cell death protein 1 (PD‐1) and its ligand 1 and 2 (PD‐L1/PD‐L2) regulate the immune system, and the checkpoint pathway can be exploited by malignant cells to evade anti‐tumor immune response. Soluble forms…
read more here.
Keywords:
spd spd;
programmed cell;
soluble programmed;
cell death ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2018 at "Critical Care"
DOI: 10.1186/s13054-018-2064-3
Abstract: Immunotherapy targeting the programmed cell death protein-1 (PD-1)–programmed cell death ligand-1 (PDL-1) axis in sepsis is poised for clinical trials, although optimal inclusion criteria and predictors of response are not well characterized. We evaluated the…
read more here.
Keywords:
sepsis;
spd;
programmed cell;
cell death ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.827921
Abstract: The immune checkpoint pathway consisting of the cell membrane-bound molecule programmed death protein 1 (PD-1) and its ligand PD-L1 has been found to mediate negative regulatory signals that effectively inhibit T-cell proliferation and function and…
read more here.
Keywords:
characteristics clinical;
spd;
cancer;
spd spd ... See more keywords